Not Signed In - The NEJM Reports BARACLUDE™ (entecavir) Demonstrated Benefits Over Lamivudine In Treating Chronically Infected Hepatitis B Patients At 48 Weeks
Fri, 10 Mar 2006 11:00 PM EST
... BARACLUDE™ (entecavir) demonstrated greater benefit in treating nucleoside-naïve chronic hepatitis B patients compared to lamivudine, the most commonly used antiviral therapy for treatment of chronic hepatitis B worldwide, according to two studies published in The New England Journal of Medicine. BARACLUDE, discovered and developed by Bristol-Myers Squibb Company (NYSE: BMY), is a prescription medicine indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease... click link for more info. ...
Related Topics
- Lamivudine
- Hepatitis C
- Hepatitis B
- Hepatitis A
- Hepatitis
- Lamivudine and Zidovudine
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Entecavir
- Autoimmune Hepatitis
- Temporary lactose intolerance afterwards (usually gets better in 1-2 weeks or less)
- Abacavir, Zidovudine and Lamivudine
- Hepatitis B Immune Globulin
- Seizures (in about half of patients)
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Smoking Cessation and Continued Risk in Cancer Patients
- Fluid collections in the pancreas (pancreatic pseudocysts) that may become infected
- Approximately one-half of patients with small tumors will get back useful hearing in the affected ear after surgery.
email this page
print this page
bookmark this page
feedback on this page
